Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Retina Associates of Cleveland, Inc.
2030
mi
from 98109
Beachwood, OH
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Retina Associates of Cleveland, Inc.
2030
mi
from 98109
Beachwood, OH
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Case Western Reserve Univ
2024
mi
from 98109
Cleveland, OH
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Case Western Reserve Univ
2024
mi
from 98109
Cleveland, OH
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
OSU Eye Physicians and Surgeons, LLC.
2008
mi
from 98109
Columbus, OH
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
OSU Eye Physicians and Surgeons, LLC.
2008
mi
from 98109
Columbus, OH
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Retina Northwest, PC
147
mi
from 98109
Portland, OR
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Retina Northwest, PC
147
mi
from 98109
Portland, OR
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Family Eye Group
2316
mi
from 98109
Lancaster, PA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Family Eye Group
2316
mi
from 98109
Lancaster, PA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
University of Pennsylvania Scheie Eye Institute
2373
mi
from 98109
Philadelphia, PA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
University of Pennsylvania Scheie Eye Institute
2373
mi
from 98109
Philadelphia, PA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Carolina Retina Center
2321
mi
from 98109
Columbia, SC
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Carolina Retina Center
2321
mi
from 98109
Columbia, SC
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Southeastern Retina Associates, PC
2150
mi
from 98109
Kingsport, TN
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Southeastern Retina Associates, PC
2150
mi
from 98109
Kingsport, TN
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Southeastern Retina Associates, P.C.
2110
mi
from 98109
Knoxville, TN
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Southeastern Retina Associates, P.C.
2110
mi
from 98109
Knoxville, TN
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
West Texas Retina Consultants P.A.
1579
mi
from 98109
Abilene, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
West Texas Retina Consultants P.A.
1579
mi
from 98109
Abilene, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Retina Research Center
1769
mi
from 98109
Austin, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Retina Research Center
1769
mi
from 98109
Austin, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Retina and Vitreous of Texas
1890
mi
from 98109
Houston, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Retina and Vitreous of Texas
1890
mi
from 98109
Houston, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Baylor Eye Physicians and Surgeons
1890
mi
from 98109
Houston, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Baylor Eye Physicians and Surgeons
1890
mi
from 98109
Houston, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Texas Retina Associates
1678
mi
from 98109
Dallas, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Texas Retina Associates
1678
mi
from 98109
Dallas, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Valley Retina Institute
1994
mi
from 98109
Harlingen, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Valley Retina Institute
1994
mi
from 98109
Harlingen, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Retinal Consultants of San Antonio
1787
mi
from 98109
San Antonio, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Retinal Consultants of San Antonio
1787
mi
from 98109
San Antonio, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Medical Center Ophthalmology Associates
1787
mi
from 98109
San Antonio, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Medical Center Ophthalmology Associates
1787
mi
from 98109
San Antonio, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Virginia Retina Center
2290
mi
from 98109
Leesburg, VA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Virginia Retina Center
2290
mi
from 98109
Leesburg, VA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
University of Washington Medical Center
2
mi
from 98109
Seattle, WA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
University of Washington Medical Center
2
mi
from 98109
Seattle, WA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Medical College of Wiconsin
1681
mi
from 98109
Milwaukee, WI
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Medical College of Wiconsin
1681
mi
from 98109
Milwaukee, WI
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
1218.61.01028 Boehringer Ingelheim Investigational Site
1039
mi
from 98109
Escondido, CA
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
1218.61.01028 Boehringer Ingelheim Investigational Site
1039
mi
from 98109
Escondido, CA
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
1218.61.01014 Boehringer Ingelheim Investigational Site
669
mi
from 98109
Greenbrae, CA
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
1218.61.01014 Boehringer Ingelheim Investigational Site
669
mi
from 98109
Greenbrae, CA
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Boehringer Ingelheim Investigational Site
962
mi
from 98109
Los Angeles, CA
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
962
mi
from 98109
Los Angeles, CA
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
1218.61.01042 Boehringer Ingelheim Investigational Site
974
mi
from 98109
Paramount, CA
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
1218.61.01042 Boehringer Ingelheim Investigational Site
974
mi
from 98109
Paramount, CA
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Boehringer Ingelheim Investigational Site
1065
mi
from 98109
San Diego, CA
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
1065
mi
from 98109
San Diego, CA
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Boehringer Ingelheim Investigational Site
2732
mi
from 98109
Miami, FL
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
2732
mi
from 98109
Miami, FL
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
1218.61.01046 Boehringer Ingelheim Investigational Site
2475
mi
from 98109
, FL
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
1218.61.01046 Boehringer Ingelheim Investigational Site
2475
mi
from 98109
, FL
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
1199.14.1178 Boehringer Ingelheim Investigational Site
2188
mi
from 98109
Lawrenceville, GA
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
1199.14.1178 Boehringer Ingelheim Investigational Site
2188
mi
from 98109
Lawrenceville, GA
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
1218.61.01038 Boehringer Ingelheim Investigational Site
2679
mi
from 98109
Honolulu, HI
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
1218.61.01038 Boehringer Ingelheim Investigational Site
2679
mi
from 98109
Honolulu, HI
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
1218.61.01040 Boehringer Ingelheim Investigational Site
399
mi
from 98109
Meridian, ID
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
1218.61.01040 Boehringer Ingelheim Investigational Site
399
mi
from 98109
Meridian, ID
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Boehringer Ingelheim Investigational Site
1733
mi
from 98109
Chicago, IL
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
1733
mi
from 98109
Chicago, IL
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
1218.61.01048 Boehringer Ingelheim Investigational Site
1813
mi
from 98109
Lafayette, IN
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
1218.61.01048 Boehringer Ingelheim Investigational Site
1813
mi
from 98109
Lafayette, IN
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
1218.61.01043 Boehringer Ingelheim Investigational Site
1882
mi
from 98109
Olive Branch, MS
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
1218.61.01043 Boehringer Ingelheim Investigational Site
1882
mi
from 98109
Olive Branch, MS
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
1218.61.01052 Boehringer Ingelheim Investigational Site
873
mi
from 98109
Las Vegas, NV
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
1218.61.01052 Boehringer Ingelheim Investigational Site
873
mi
from 98109
Las Vegas, NV
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
1218.61.01029 Boehringer Ingelheim Investigational Site
2403
mi
from 98109
Brooklyn, NY
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
1218.61.01029 Boehringer Ingelheim Investigational Site
2403
mi
from 98109
Brooklyn, NY
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Boehringer Ingelheim Investigational Site
2401
mi
from 98109
New York, NY
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
2401
mi
from 98109
New York, NY
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
1218.61.01007 Boehringer Ingelheim Investigational Site
2297
mi
from 98109
Greensboro, NC
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
1218.61.01007 Boehringer Ingelheim Investigational Site
2297
mi
from 98109
Greensboro, NC
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
1218.61.01004 Boehringer Ingelheim Investigational Site
2459
mi
from 98109
Jacksonville, NC
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
1218.61.01004 Boehringer Ingelheim Investigational Site
2459
mi
from 98109
Jacksonville, NC
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
1218.61.01023 Boehringer Ingelheim Investigational Site
2455
mi
from 98109
Wilmington, NC
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
1218.61.01023 Boehringer Ingelheim Investigational Site
2455
mi
from 98109
Wilmington, NC
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
1218.61.01027 Boehringer Ingelheim Investigational Site
1929
mi
from 98109
Perrysburg, OH
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
1218.61.01027 Boehringer Ingelheim Investigational Site
1929
mi
from 98109
Perrysburg, OH
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
1218.61.01031 Boehringer Ingelheim Investigational Site
2487
mi
from 98109
East Providence, RI
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
1218.61.01031 Boehringer Ingelheim Investigational Site
2487
mi
from 98109
East Providence, RI
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
1218.61.01017 Boehringer Ingelheim Investigational Site
2235
mi
from 98109
Simpsonville, SC
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
1218.61.01017 Boehringer Ingelheim Investigational Site
2235
mi
from 98109
Simpsonville, SC
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Boehringer Ingelheim Investigational Site
1681
mi
from 98109
Dallas, TX
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
1681
mi
from 98109
Dallas, TX
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Boehringer Ingelheim Investigational Site
1890
mi
from 98109
Houston, TX
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
1890
mi
from 98109
Houston, TX
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
1218.61.01003 Boehringer Ingelheim Investigational Site
1888
mi
from 98109
Sugar Land, TX
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
1218.61.01003 Boehringer Ingelheim Investigational Site
1888
mi
from 98109
Sugar Land, TX
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
1218.61.01041 Boehringer Ingelheim Investigational Site
1763
mi
from 98109
Tyler, TX
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
1218.61.01041 Boehringer Ingelheim Investigational Site
1763
mi
from 98109
Tyler, TX
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
1218.61.01024 Boehringer Ingelheim Investigational Site
2372
mi
from 98109
Bennington, VT
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
1218.61.01024 Boehringer Ingelheim Investigational Site
2372
mi
from 98109
Bennington, VT
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
1199.14.1259 Boehringer Ingelheim Investigational Site
229
mi
from 98109
Spokane, WA
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone
Status: Archived
Updated: 1/1/1970
1199.14.1259 Boehringer Ingelheim Investigational Site
229
mi
from 98109
Spokane, WA
Diabetes and Periodontal Therapy Trial
A Multicenter Randomized Single-Masked Clinical Trial Testing the Effect of Non-surgical Periodontal Therapy on Glycosylated Hemoglobin (HbA1c) Levels in Subjects With Type 2 Diabetes and Chronic Periodontitis
Status: Archived
Clinical Site: University of Alabama at Birmingham
2072
mi
from 98109
Birmingham, AL
Diabetes and Periodontal Therapy Trial
A Multicenter Randomized Single-Masked Clinical Trial Testing the Effect of Non-surgical Periodontal Therapy on Glycosylated Hemoglobin (HbA1c) Levels in Subjects With Type 2 Diabetes and Chronic Periodontitis
Status: Archived
Updated: 1/1/1970
Clinical Site: University of Alabama at Birmingham
2072
mi
from 98109
Birmingham, AL
Diabetes and Periodontal Therapy Trial
A Multicenter Randomized Single-Masked Clinical Trial Testing the Effect of Non-surgical Periodontal Therapy on Glycosylated Hemoglobin (HbA1c) Levels in Subjects With Type 2 Diabetes and Chronic Periodontitis
Status: Archived
University of Minnesota Medical Center
1393
mi
from 98109
Minneapolis, MN
Diabetes and Periodontal Therapy Trial
A Multicenter Randomized Single-Masked Clinical Trial Testing the Effect of Non-surgical Periodontal Therapy on Glycosylated Hemoglobin (HbA1c) Levels in Subjects With Type 2 Diabetes and Chronic Periodontitis
Status: Archived
Updated: 1/1/1970
University of Minnesota Medical Center
1393
mi
from 98109
Minneapolis, MN